Michael J McCluskie

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. pmc Selection of a novel anti-nicotine vaccine: influence of antigen design on antibody function in mice
    David C Pryde
    Pfizer Worldwide Medicinal Chemistry, Cambridge, United Kingdom
    PLoS ONE 8:e76557. 2013
  2. doi request reprint Enhancing immunogenicity of a 3'aminomethylnicotine-DT-conjugate anti-nicotine vaccine with CpG adjuvant in mice and non-human primates
    Michael J McCluskie
    Pfizer Vaccine Research, Ottawa, ON, Canada
    Int Immunopharmacol 16:50-6. 2013
  3. pmc CpG ODN and ISCOMATRIX adjuvant: a synergistic adjuvant combination inducing strong T-Cell IFN-γ responses
    Michael J McCluskie
    Pfizer Vaccine Research, Ottawa Laboratories, 340 Terry Fox Drive, Suite 200, Ottawa, ON, Canada K2K 3A2
    Biomed Res Int 2013:636847. 2013
  4. ncbi request reprint Testing of CpG-optimized protein and DNA vaccines against the hepatitis B virus in chimpanzees for immunogenicity and protection from challenge
    Paul J Payette
    Coley Pharmaceutical Canada, Ottawa, Canada
    Intervirology 49:144-51. 2006
  5. ncbi request reprint Treatment of intravaginal HSV-2 infection in mice: a comparison of CpG oligodeoxynucleotides and resiquimod (R-848)
    Michael J McCluskie
    Coley Pharmaceutical Group, 340 Terry Fox Drive, Suite 200, Ottawa, Ont, Canada K2K 3A2
    Antiviral Res 69:77-85. 2006
  6. ncbi request reprint TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848)
    Risini D Weeratna
    Coley Pharmaceutical Group, Suite 200, Ottawa, ON, Canada K2K 3A2
    Vaccine 23:5263-70. 2005
  7. ncbi request reprint Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA
    Michael J McCluskie
    Coley Pharmaceutical Group, 725 Parkdale Avenue, K1Y 4E9, Ottawa, ON, Canada
    FEMS Immunol Med Microbiol 32:179-85. 2002

Collaborators

Detail Information

Publications7

  1. pmc Selection of a novel anti-nicotine vaccine: influence of antigen design on antibody function in mice
    David C Pryde
    Pfizer Worldwide Medicinal Chemistry, Cambridge, United Kingdom
    PLoS ONE 8:e76557. 2013
    ..While both Ab titer and affinity contributed to function, affinity was more sensitive to antigen differences. ..
  2. doi request reprint Enhancing immunogenicity of a 3'aminomethylnicotine-DT-conjugate anti-nicotine vaccine with CpG adjuvant in mice and non-human primates
    Michael J McCluskie
    Pfizer Vaccine Research, Ottawa, ON, Canada
    Int Immunopharmacol 16:50-6. 2013
    ..Further improvement should focus on maximizing Ab function, which takes into account both titer and avidity, and this may require improved conjugate design in addition to adjuvants...
  3. pmc CpG ODN and ISCOMATRIX adjuvant: a synergistic adjuvant combination inducing strong T-Cell IFN-γ responses
    Michael J McCluskie
    Pfizer Vaccine Research, Ottawa Laboratories, 340 Terry Fox Drive, Suite 200, Ottawa, ON, Canada K2K 3A2
    Biomed Res Int 2013:636847. 2013
    ..Thus the CpG/ISCOMATRIX combination may prove to be a valuable tool in the development of novel or improved vaccines...
  4. ncbi request reprint Testing of CpG-optimized protein and DNA vaccines against the hepatitis B virus in chimpanzees for immunogenicity and protection from challenge
    Paul J Payette
    Coley Pharmaceutical Canada, Ottawa, Canada
    Intervirology 49:144-51. 2006
    ..The poor results may be due to an inadequate number of doses or amount of plasmid DNA in these larger animals, but nevertheless point to the need to improve delivery methods for DNA vaccines for use in larger animals such as primates...
  5. ncbi request reprint Treatment of intravaginal HSV-2 infection in mice: a comparison of CpG oligodeoxynucleotides and resiquimod (R-848)
    Michael J McCluskie
    Coley Pharmaceutical Group, 340 Terry Fox Drive, Suite 200, Ottawa, Ont, Canada K2K 3A2
    Antiviral Res 69:77-85. 2006
    ....
  6. ncbi request reprint TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848)
    Risini D Weeratna
    Coley Pharmaceutical Group, Suite 200, Ottawa, ON, Canada K2K 3A2
    Vaccine 23:5263-70. 2005
    ..Using HBsAg as a model antigen in mice, we show CpG ODN to be superior to R-848 for augmenting both humoral and cell mediated immune responses...
  7. ncbi request reprint Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA
    Michael J McCluskie
    Coley Pharmaceutical Group, 725 Parkdale Avenue, K1Y 4E9, Ottawa, ON, Canada
    FEMS Immunol Med Microbiol 32:179-85. 2002
    ..Th2). Mice primed intranasally could have their systemic immune responses boosted with a parenteral administration and it was also possible to enhance mucosal responses induced by intranasal prime with an intramuscular boost...